

RELEASE OF SHARES FROM VOLUNTARY ESCROW

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'AROA' or the 'Company') advises, in accordance with ASX Listing Rule 3.10A, that 70,055 fully paid ordinary shares will be released from voluntary escrow on 31 March 2026. These shares are in addition to the 70,055 fully paid ordinary shares that were released from voluntary escrow on 31 March 2025. The two tranches taken together ('Escrowed Shares') represents 0.04 % of the Company's issued share capital.

The Escrowed Shares were issued on 22 August 2024 to Ms Darla Hutton, Non-Executive Director, following shareholder approval received at the Company's 2024 Annual General Meeting. These shares are already quoted on ASX.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for *everybody*'.

We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach.

Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc.

Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contact

investor@aroa.com